{"id":49259,"date":"2026-11-14T13:51:00","date_gmt":"2026-11-14T13:51:00","guid":{"rendered":"https:\/\/en.prnasia.com\/story\/archive\/5097936_AE97936_0"},"modified":"2026-11-14T13:51:00","modified_gmt":"2026-11-14T13:51:00","slug":"ajovy-formally-included-in-chinas-national-reimbursement-drug-list-2026","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=49259","title":{"rendered":"AJOVY\u00ae Formally Included in China&#8217;s National Reimbursement Drug List 2026"},"content":{"rendered":"<p><span class=\"legendSpanClass\">SHANGHAI<\/span>, <span class=\"legendSpanClass\">Nov. 14, 2026<\/span> \/PRNewswire\/ &#8212; On November 14,&nbsp;NeuroGen announced that it&#8217;s in-licensed innovative drug <b>AJOVY<sup>\u00ae<\/sup><\/b> (fremanezumab injection) from TEVA has been successfully listed on China&#8217;s National Reimbursement Drug List (NRDL) following the latest round of national price negotiations<sup>1<\/sup>. Marking a breakthrough as the first&nbsp;CGRP inhibitor covered by national insurance, <b>AJOVY<sup>\u00ae <\/sup><\/b>achieved same-year NRDL inclusion after its initial approval in June\u2014a milestone expected to dramatically improve patient access and relieve the long-term financial burden for patients in China living with migraine.<\/p>\n<ul type=\"disc\">\n<li><b>AJOVY<sup>\u00ae<\/sup><\/b> is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand<sup>2<\/sup><\/li>\n<li>Among currently marketed anti-CGRP monoclonal antibodies, fremanezumab injection is the only subcutaneous therapy offering both monthly and quarterly dosing options<sup>3<\/sup><\/li>\n<li>Supported by multiple pivotal clinical studies, fremanezumab injection has proven effective and safe in adult migraine prevention, serving as the sole CGRP mAb to evaluate efficacy through a standalone Phase III trial in Chinese patients<sup>4,5,6,7<\/sup><\/li>\n<\/ul>\n<p><b>Sean Chen, Chief Executive Officer of NeuroGen Pharma, <\/b>stated: <span id=\"spanHghltdd75\">&#8220;<\/span><b><span id=\"spanHghltf69c\">F<\/span>remanezumab Injection&#8217;s inclusion in the NRDL<\/b> within the same year of approval reflects strong policy support for clinically needed innovation. As a key in-licensed product accelerating our local delivery of global innovations, its enhanced accessibility will bring breakthrough clinical benefits and financial relief to migraine patients. NeuroGen is fully committed to securing a steady nationwide supply, bringing cutting-edge innovation to benefit more families faster.&#8221;<\/p>\n<p>Migraine is a common chronic neurological disease. Evidence suggests that approximatel<span id=\"spanHghlt8d00\">y 1<\/span>00 million individuals in China live with migraine<sup>8<\/sup>, with a 9.3% annual prevalence rate among adults aged 18 to 65<sup>9<\/sup>. Characterized by a substantial disease burden and recurrent attacks, migraine persistently impacts patients&#8217; work productivity, social activities, and overall quality of life<sup>8<\/sup>. Reducing attack frequency and mitigating its impact on daily life are therefore crucial goals in adult migraine management<sup>9<\/sup>.<\/p>\n<p><b>AJOVY<sup>\u00ae<\/sup><\/b><b>&nbsp;in China:<\/b><\/p>\n<ul type=\"disc\">\n<li><b>2023<\/b>&#8211; It was approved by the Guangdong Provincial Medical Products Administration, pioneering the &#8220;Hong Kong and Macao Medicine and Equipment Connect&#8221; policy in the Guangdong-Hong Kong-Macao Greater Bay Area;<\/li>\n<li><b>2024<\/b>&#8211; Fremanezumab met its primary and all secondary endpoints in a China Phase III study, demonstrating efficacy in the Chinese population<sup>13<\/sup>;<\/li>\n<li><b>April 2026<\/b>&#8211; NeuroGen entered a strategic partnership with Teva, obtaining exclusive commercialization rights in China<sup>14<\/sup>;<\/li>\n<li><b>June 2026<\/b>&#8211; It was approved by the NMPA for the preventive treatment of migraine in adults<sup>15<\/sup>;<\/li>\n<li><b>November 2026<\/b>&#8211; It was formally included in the China NRDL<sup>1<\/sup>.<\/li>\n<\/ul>\n<p>CGRP-targeted monoclonal antibodies, representing a core novel mechanism in preventive migraine therapy, are explicitly recommended across multiple domestic and international landmark guidelines. Key endorsees include the <i>Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update<sup>11<\/sup><\/i>&nbsp;the <i>Chinese Guidelines for the Diagnosis and Treatment of Migraine<sup>9<\/sup><\/i>, the <i>Chinese practice guidelines for diagnosis and treatment of migraine<sup>10<\/sup> <\/i>and the <i>Chinese expert consensus on the diagnosis and treatment of medication overuse headache<sup>12<\/sup><\/i>.<\/p>\n<p><b>About AJOVY<sup>\u00ae<\/sup> (Fremanezumab Injection)<\/b><\/p>\n<p>AJOVY is an innovative migraine treatment developed by Teva Pharmaceuticals and it offers both monthly (225mg) and quarterly (675mg) subcutaneous dosing options<sup>16<\/sup>. Among currently marketed&nbsp;anti-CGRP monoclonal antibodies, AJOVY is the only therapy offering these two dosing regimens<sup>3<\/sup>. The quarterly dosing option significantly reduces injection frequency, helping patients adhere to treatment and sustain long-term control of migraine attacks. The efficacy and safety of&nbsp;AJOVY are supported by multiple clinical studies. A China Phase III study in adult migraine demonstrated a significant reduction in monthly migraine days with a favorable safety profile<sup>4<\/sup>.<\/p>\n<p>It was first approved in adults by the U.S. Food and Drug Administration (FDA) in 2018<sup>3<\/sup> and by the European Medicines Agency (EMA) in 2019<sup>3<\/sup>. In 2025,&nbsp;AJOVY was approved by the FDA for single-dose injection use in children and adolescents aged 6\u201317 years with episodic migraine weighing 45 kg or more, becoming the world&#8217;s first and only CGRP antagonist approved for both pediatric episodic migraine prevention and adult migraine prevention<sup>3<\/sup>.<\/p>\n<p><b>About NeuroGen <\/b><\/p>\n<p>NeuroGen Pharma was established in 2024 when Mubadala Investment Company and C-Bridge Capital jointly carved out CNS and Allergy originator portfolios of UCB and its Zhuhai Manufacturing site in China.<\/p>\n<p>Leveraging its end-to-end capabilities covering R&amp;D, manufacturing, and commercialization, NeuroGen focuses on addressing unmet clinical needs in neurology and allergy, with synergistic expansions into pain management. The company is building a scalable, growth-oriented biopharmaceutical platform dedicated to transforming care for better patient outcomes.<\/p>\n<p>Visit us at <a href=\"https:\/\/www.neurogen.com.cn\/\" target=\"_blank\" rel=\"nofollow\">www.neurogen.com.cn<\/a> to learn more.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody readability=\"30.5\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">\u53c2\u8003\u6587\u732e\uff1a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"3\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1.&nbsp; \u56fd\u5bb6\u57fa\u672c\u533b\u7597\u4fdd\u9669\u3001\u5de5\u4f24\u4fdd\u9669\u548c\u751f\u80b2\u4fdd\u9669\u836f\u54c1\u76ee\u5f55\uff082026\u5e74\uff09<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">2.&nbsp; Mitsikostas D, et al. Pain Manag. 2025 Nov;15(11):791-800.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3.&nbsp; \u827e\u4e45\u7ef4_\u5728\u534e\u83b7\u6279\uff0c\u7075\u6d3b\u7ed9\u836f\u4e3a\u504f\u5934\u75db\u957f\u671f\u7ba1\u7406\u5e26\u6765\u65b0\u9009\u62e9 https:\/\/mp.weixin.qq.com\/s\/4dmPgbvVKRPhzPhuBQZZ_w<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"7.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">4.&nbsp; Yu S, et al. Cephalalgia, 2026, 46(8): 1\u201313.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">5.&nbsp; Silberstein SD, et al. N Engl J Med. 2017 Nov 30;377(22):2113-2122.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6.&nbsp; Dodick DW, et al. JAMA. 2018 May 15;319(19):1999-2008.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">7.&nbsp; Ferrari MD, et al. Lancet. 2019 Sep 21;394(10203):1030-1040.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8.&nbsp; Wang YX, et al. J Headache Pain. 2025 May 6;26(1):104.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"7.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">9.&nbsp; \u4e2d\u56fd\u533b\u5e08\u534f\u4f1a\u795e\u7ecf\u5185\u79d1\u533b\u5e08\u5206\u4f1a, \u7b49. \u4e2d\u56fd\u75bc\u75db\u533b\u5b66\u6742\u5fd7, 2022,28(12)881-898.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"7.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.&nbsp; \u4e2d\u534e\u533b\u5b66\u4f1a\u795e\u7ecf\u75c5\u5b66\u5206\u4f1a, \u7b49. \u4e2d\u534e\u795e\u7ecf\u79d1\u6742\u5fd7,2023,56(6):591-613.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"7.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">11.&nbsp; Charles AC, et al.&nbsp; Headache, 2024, 64(4): 333-341.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"7.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">12.&nbsp; \u4e2d\u534e\u533b\u5b66\u4f1a\u795e\u7ecf\u75c5\u5b66\u5206\u4f1a\u5934\u75db\u534f\u4f5c\u7ec4, \u7b49. \u4e2d\u534e\u795e\u7ecf\u79d1\u6742\u5fd7\uff0c2026, 59 (1): 18\u201333.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"15\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"13\">\n<p class=\"prnml4\"><span class=\"prnews_span\">13.&nbsp; Efficacy Outcomes From a Phase 3, Randomised, Double\u2013Blind, Placebo\u2013Controlled Study of Fremanezumab for the Preventive Treatment of Migraine in Chinese Adults[C]. 20th Migraine Trust International Symposium, London, UK, 2024.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"3\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">14.&nbsp; \u795e\u57fa\u5236\u836f\u5b98\u7f51\u516c\u544a.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"3\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">15.&nbsp; 2026\u5e7406\u670808\u65e5\u836f\u54c1\u6279\u51c6\u8bc1\u660e\u6587\u4ef6\u9001\u8fbe\u4fe1\u606f.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"3\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">16.&nbsp; \u592b\u745e\u5948\u73e0\u5355\u6297\u6ce8\u5c04\u6db2\u8bf4\u660e\u4e66. 2026\u5e7406\u670803\u65e5.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, Nov. 14, 2026 \/PRNewswire\/ &#8212; On November 14,&nbsp;NeuroGen announced that it&#8217;s in-licensed innovative drug AJOVY\u00ae (fremanezumab injection) from TEVA has been successfully listed on China&#8217;s National Reimbursement Drug List (NRDL) following the latest round of national price negotiations1. Marking a breakthrough as the first&nbsp;CGRP inhibitor covered by national insurance, AJOVY\u00ae achieved same-year NRDL inclusion [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-49259","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AJOVY\u00ae Formally Included in China&#039;s National Reimbursement Drug List 2026 - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=49259\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AJOVY\u00ae Formally Included in China&#039;s National Reimbursement Drug List 2026 - My Blog\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, Nov. 14, 2026 \/PRNewswire\/ &#8212; On November 14,&nbsp;NeuroGen announced that it&#8217;s in-licensed innovative drug AJOVY\u00ae (fremanezumab injection) from TEVA has been successfully listed on China&#8217;s National Reimbursement Drug List (NRDL) following the latest round of national price negotiations1. Marking a breakthrough as the first&nbsp;CGRP inhibitor covered by national insurance, AJOVY\u00ae achieved same-year NRDL inclusion [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=49259\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-14T13:51:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"AJOVY\u00ae Formally Included in China&#8217;s National Reimbursement Drug List 2026\",\"datePublished\":\"2026-11-14T13:51:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259\"},\"wordCount\":834,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259\",\"name\":\"AJOVY\u00ae Formally Included in China's National Reimbursement Drug List 2026 - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2026-11-14T13:51:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49259#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AJOVY\u00ae Formally Included in China&#8217;s National Reimbursement Drug List 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AJOVY\u00ae Formally Included in China's National Reimbursement Drug List 2026 - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=49259","og_locale":"en_US","og_type":"article","og_title":"AJOVY\u00ae Formally Included in China's National Reimbursement Drug List 2026 - My Blog","og_description":"SHANGHAI, Nov. 14, 2026 \/PRNewswire\/ &#8212; On November 14,&nbsp;NeuroGen announced that it&#8217;s in-licensed innovative drug AJOVY\u00ae (fremanezumab injection) from TEVA has been successfully listed on China&#8217;s National Reimbursement Drug List (NRDL) following the latest round of national price negotiations1. Marking a breakthrough as the first&nbsp;CGRP inhibitor covered by national insurance, AJOVY\u00ae achieved same-year NRDL inclusion [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=49259","og_site_name":"My Blog","article_published_time":"2026-11-14T13:51:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=49259#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49259"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"AJOVY\u00ae Formally Included in China&#8217;s National Reimbursement Drug List 2026","datePublished":"2026-11-14T13:51:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49259"},"wordCount":834,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=49259","url":"https:\/\/transmediavictoria.net.au\/?p=49259","name":"AJOVY\u00ae Formally Included in China's National Reimbursement Drug List 2026 - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2026-11-14T13:51:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49259#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=49259"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=49259#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"AJOVY\u00ae Formally Included in China&#8217;s National Reimbursement Drug List 2026"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/49259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49259"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/49259\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}